Insmed discontinues development of skin condition drug after mid-stage study miss
April 7 (Reuters) - Insmed INSM.O said on Tuesday it would discontinue the development of its treatment for a chronic, inflammatory skin condition, after the drug failed a mid-stage trial.
The drug, brensocatib, did not meet the main goal of reducing painful lumps in patients with hidradenitis suppurativa, the company said.
"While we are disappointed in the results, we hope that insights gained from this study will contribute to the broader scientific understanding of HS," said Insmed's Chief Medical Officer, Martina Flammer.
The drug was generally safe, with no new safety signals, the company said. It plans to present the data at a future meeting.
Insmed said in December it discontinued the development of brensocatib as a treatment for a chronic sinus condition after a trial failure.
Brensocatib, branded as Brinsupri, is approved in the U.S. to treat non-cystic fibrosis bronchiectasis, a chronic lung condition characterized by permanently damaged airways.
